CellCarta and Biofidelity Forge Exclusive Partnership for Aspyre® Lung Testing CellCarta and Biofidelity have expanded their partnership to exclusively offer Aspyre® Lung for targeted lung cancer testing, streamlining clinical trials.

CellCarta and Biofidelity Forge Exclusive Partnership for Aspyre® Lung Testing #Cambridge #United_Kingdom #Biofidelity #CellCarta #Aspyre_Lung

Welcome Biofidelity to the BLOODPAC Consortium! Their technologies aim to advance precision oncology and improve access to high-quality genomic insights. We’re excited to work together to accelerate progress across the liquid biopsy ecosystem.

#BLOODPAC #Biofidelity

Biofidelity Unveils Revolutionary Enspyre® Technology at AGBT 2025 Biofidelity is set to debut its groundbreaking sequencing technology, Enspyre®, aimed at enhancing genomic analysis for cancer diagnostics at AGBT 2025.

Biofidelity Unveils Revolutionary Enspyre® Technology at AGBT 2025 #United_States #Florida #Biofidelity #Enspyre #Genomic_Technology

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials - PharmaTimes New partnership to advance precision medicine in lung cancer diagnosis

#genomicsolutions #MolecularDiagnostics #Biofidelity #oncology #genomics4all #CellCarta #AspyreLung #precisionmedicine #nonsmallcelllungcancer #NSCLC #NSCLCbiomarkers #genomicservices #clinicaltrialenrolment #SimplifiedGenomicProfiling #SGP #qPCRplatforms
pharmatimes.com/news/biofide...

Biofidelity and CellCarta's Innovative Approach to Clinical Trials Launching Aspyre® Lung Biofidelity partners with CellCarta to implement Aspyre® Lung in global clinical trials, advancing cancer diagnosis with innovative genomic solutions.

Biofidelity and CellCarta's Innovative Approach to Clinical Trials Launching Aspyre® Lung #Cambridge #United_Kingdom #Biofidelity #CellCarta #Aspyre_Lung